Merck & Co., Inc. (NYSE:MRK) Price Target Raised to $170.00

Merck & Co., Inc. (NYSE:MRK) had its target price boosted by BMO Capital Markets from $142.00 to $170.00 in a research report released on Thursday,Benzinga reports. BMO Capital Markets currently has an outperform rating on the stock.

A number of other research analysts have also issued reports on MRK. CICC Research initiated coverage on shares of Merck & Co., Inc. in a research note on Wednesday, June 24th. They set an “outperform” rating and a $138.00 price target on the stock. Barclays raised their price objective on shares of Merck & Co., Inc. from $140.00 to $150.00 and gave the company an “overweight” rating in a research report on Wednesday, July 29th. Bank of America lifted their price objective on Merck & Co., Inc. from $130.00 to $141.00 and gave the company a “buy” rating in a report on Tuesday, June 30th. UBS Group boosted their target price on Merck & Co., Inc. from $145.00 to $175.00 and gave the stock a “buy” rating in a research report on Thursday. Finally, Jefferies Financial Group downgraded Merck & Co., Inc. from a “strong-buy” rating to a “hold” rating in a research note on Wednesday. Fifteen analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the stock. According to data from MarketBeat.com, Merck & Co., Inc. currently has a consensus rating of “Moderate Buy” and a consensus target price of $144.10.

Merck & Co., Inc. Stock Performance

Shares of MRK opened at $152.43 on Thursday. The company has a debt-to-equity ratio of 1.22, a quick ratio of 1.10 and a current ratio of 1.32. The stock has a market capitalization of $376.07 billion, a P/E ratio of 121.94, a P/E/G ratio of 6.58 and a beta of 0.19. The company’s fifty day moving average is $128.09 and its two-hundred day moving average is $121.23. Merck & Co., Inc. has a 1 year low of $77.58 and a 1 year high of $154.49.

Merck & Co., Inc. (NYSE:MRK) last released its earnings results on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.13. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The company had revenue of $16.61 billion during the quarter, compared to analysts’ expectations of $16.37 billion. During the same quarter last year, the business earned $2.13 EPS. The business’s revenue was up 5.1% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. On average, sell-side analysts predict that Merck & Co., Inc. will post 2.76 earnings per share for the current year.

Merck & Co., Inc. Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th will be paid a $0.85 dividend. The ex-dividend date is Tuesday, September 15th. This represents a $3.40 annualized dividend and a dividend yield of 2.2%. Merck & Co., Inc.’s dividend payout ratio (DPR) is 272.00%.

Insider Activity

In other Merck & Co., Inc. news, EVP Chirfi Guindo sold 10,000 shares of the stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $135.00, for a total value of $1,350,000.00. Following the completion of the transaction, the executive vice president directly owned 36,613 shares of the company’s stock, valued at approximately $4,942,755. This trade represents a 21.45% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP David R. Maraldo sold 18,706 shares of Merck & Co., Inc. stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $128.72, for a total transaction of $2,407,836.32. Following the sale, the executive vice president owned 18,212 shares of the company’s stock, valued at approximately $2,344,248.64. The trade was a 50.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 228,238 shares of company stock valued at $29,977,783 in the last quarter. Insiders own 0.17% of the company’s stock.

Institutional Investors Weigh In On Merck & Co., Inc.

Institutional investors and hedge funds have recently modified their holdings of the company. Kingdom Financial Group LLC. acquired a new position in Merck & Co., Inc. during the fourth quarter worth $25,000. Abound Financial LLC acquired a new stake in Merck & Co., Inc. in the fourth quarter valued at $26,000. Prosperity Bancshares Inc acquired a new stake in Merck & Co., Inc. in the fourth quarter valued at $26,000. High Note Wealth LLC increased its position in shares of Merck & Co., Inc. by 58.9% in the fourth quarter. High Note Wealth LLC now owns 294 shares of the company’s stock valued at $31,000 after buying an additional 109 shares in the last quarter. Finally, IFC & Insurance Marketing Inc. purchased a new position in shares of Merck & Co., Inc. in the fourth quarter valued at $31,000. Institutional investors and hedge funds own 76.07% of the company’s stock.

Merck & Co., Inc. News Summary

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck and Moderna reported that their personalized cancer therapy met key Phase 3 goals, improving recurrence-free and distant metastasis-free survival for high-risk melanoma patients when added to Keytruda. The result is the first major late-stage win for an mRNA cancer vaccine and strengthens the potential for regulatory approval and broader oncology applications. MRK/MRNA’s Personalized Cancer Therapy Delivers First Phase III Win
• Positive Sentiment: Several Wall Street firms raised their outlooks for MRK: Goldman Sachs increased its price target to $160 and kept a Buy rating, while BMO raised its target to $170 and UBS lifted its target to $175. Morgan Stanley also upgraded the shares to Overweight with a $179 target after the cancer-trial success.
• Positive Sentiment: Investors see Merck’s newer products, acquired assets and pipeline programs as a potential growth cushion against Keytruda’s eventual patent expiration. The company’s expanding portfolio could help diversify revenue beyond its flagship drug. Can Merck’s New Drugs Offer Growth Cushion Ahead of Keytruda LOE?
• Neutral Sentiment: Unusually high options activity indicates heightened investor interest and potential volatility, but it does not by itself establish the direction of the stock.
• Negative Sentiment: RBC Capital Markets downgraded Merck to Sector Perform and set a $150 target, arguing that execution risks and the 2028 Keytruda loss of exclusivity are being underestimated. RBC said near-term catalysts are attractive, but the stock’s valuation leaves limited room for additional gains. Merck upgraded at Morgan Stanley after cancer trial win; RBC downgrades
• Negative Sentiment: Jefferies separately moved Merck from Strong Buy to Hold. The central concern is that the shares have already rallied substantially on the trial news, making the current valuation appear demanding relative to the remaining patent and execution risks.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.